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3INTRODUCTION
The menopause is associated with an increase
in bone resorption rate which may contribute to os-
teoporosis, for which the main consequence is an in-
creased risk of fractures.1 Hormone replacement
therapy (HRT) has been shown to be the most effi-
cient prevention and treatment of osteoporosis.2 Ac-
celerated postmenopausal bone loss is attributed to
an increase in bone turnover, considering both bone
formation and resorption due to ovarian failure, with
the predominance of resorption.3,4
Bone formation may be evaluated through dif-
ferent biochemical markers, such as serum concentra-
tion of osteocalcine, alkaline phosphatase and the car-
boxyl terminal pro-peptide of type I procollagen.5 How-
ever, it has been difficult to establish a sensitive resorp-
tion marker. Most studies on the postmenopause pe-
riod are based on the determination of urinary hydrox-
yproline, which is not specific for bone collagen but is a
fraction originating from skin collagen, which also de-
creases in the postmenopausal period.6
Urinary pyridinoline (pyr) and deoxypyridinoline
(d-pyr) excretion has been used as a new bone resorp-
tion marker. Pyr and d-pyr are non-reducible interlinking
molecules of bone collagen, not subject to significant
metabolism in the body and are released during their
degradation. Although collagen is the major compo-
nent of several connective tissues, pyr is abundant in
bone and cartilage, and d-pyr seems to be present in
significant amounts only in bone.7,8 Therefore, urinary
excretion of pyr and d-pyr may reflect the bone matrix
degradation process in a sensitive way.
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abstract
CONTEXT: The menopause accelerates bone loss and is associated
with an increased bone turnover. Bone formation may be evaluated
by several biochemical markers. However, the establishment of an
accurate marker for bone resorption has been more difficult to
achieve.
OBJECTIVE: To study the effect of hormone replacement therapy (HRT)
on bone mass and on the markers of bone resorption: urinary excre-
tion of pyridinoline and deoxypyridinoline.
DESIGN: Cohort correlational study.
SETTING: Academic referral center.
SAMPLE: 53 post-menopausal women, aged 48-58 years.
MAIN MEASUREMENTS: Urinary pyr and d-pyr were measured in
fasting urine samples by spectrofluorometry after high performance
liquid chromatography and corrected for creatinine excretion mea-
sured before treatment and after 1, 2, 4 and 12 months. Bone min-
eral density (BMD) was measured by dual energy X-ray
absorptiometry (DEXA) before treatment and after 12 months of HRT.
RESULTS: The BMD after HRT was about 4.7% (P < 0.0004); 2% (P
< 0.002); and 3% (P < 0.01) higher than the basal values in lumbar
spine, neck and trochanter respectively. There were no significant
correlations between pyridinium cross-links and age, weight, meno-
pause duration and BMD. The decrease in pyr and d-pyr was pro-
gressive after HRT, reaching 28.9% (P < 0.0002), and 42% (P <
0.0002) respectively after 1 year.
CONCLUSIONS: Urinary pyridinoline and deoxypyridinoline excre-
tion decreases early in hormone replacement therapy, reflecting a
decrease in the bone resorption rate, and no correlation was ob-
served with the bone mass evaluated by densitometry.
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4The purpose of this study was to determine the
validity of these markers in the early evaluation of the
efficacy of hormone replacement therapy in relation
to bone resorption in menopausal women.
METHODS
The procedures that follow were in accordance
with the ethical standards of the comittee responsible
for human experimentation and with the Helsinki dec-






The study consisted of 53 women with menopause
of 3.6 years (SD 5) before the study, and ages of 53 years
(SD 5 median 50 years) and body mass index (BMI) of 26
kg/m2 (SD 4). They were healthy women without previ-
ous use of any hormonal or other medication that could
affect bone metabolism. Calcium intake, as assessed by
questioning about food, was between 500 and 1000 mg/
day in 26% and below 500 mg/day in 74% of the patients.
Menopause was defined as amenorrhea for more than 6
months and/or FSH serum levels over or equal to 40 mIU/
L. In 96% of the women the menopause was spontane-
ous and mean FSH levels were 65.9 mIU/L (SD 27.2).
Study Procedures
The patients were submitted to standard question-
ing, physical and gynecological examination and, when
included in the study, bone mineral density (BMD) of
the column and femur, serum gonadotrophin (LH, FSH),
estradiol and urinary pyridinoline and deoxypyridinoline
determinations were performed. Then the patients
started hormone replacement therapy with 100 mcg/week
transdermal estradiol (Estraderm) and 5 mg/day/12days/
month oral medroxyprogesterone (Farlutal), except for
two patients who had hysterectomies and used only es-
tradiol.
Main Outcomes
Pyr and d-pyr were assayed in urine after 2 h
fasting. Urine samples were collected after 1, 2, 4 and
12 months of HRT for pyr and d-pyr evaluation and BD
was repeated after 12 months of HRT. The urine was
hydrolyzed and submitted to CF1 cellulose chroma-
tography. The extracted product was separated by
HPLC and identified using fluorescein. Pyr and d-pyr
results were expressed as pmol/µmol creatinine.9 The
inter-assay variation coefficient was 12.4% for pyr and
10.8% for d-pyr and the intra-assay was 0.6% for pyr
and 6.7% for d-pyr.
Bone densitometry was done using a double en-
ergy X-ray absorption apparatus (Lunar Radiation DPX,
Madison, WI) with a variation coefficient of approxi-
mately 1.5% for both the column and the femoral neck.
Estradiol and gonadotrophin levels were deter-
mined by radioimmunoassay.
Statistical Methods
Paired and non-paired t tests were used to com-
pare variables within the same group at the beginning
and after the treatment and to compare variables be-
tween the groups, respectively. To evaluate values re-
peated throughout the experiment, variance analysis
was used and complemented with Tukey’s contrast
test. In order to correlate the two variables we used
Pearson’s correlation test. The level of significance was
set at P < 0.05 (5%). Results shown in the text and
tables are expressed as mean and standard deviation.
RESULTS
After 1 month of HRT d-pyr values already pre-
sented a decrease of 34% when compared with the
baseline values (P < 0.001), and at 2 months, the pyr
decrease was 14% (P < 0.05). The decrease progressed
up to 1 year of HRT reaching 28.9% (P < 0.0002) for pyr
and 42% (P < 0.0002) for d-pyr (Table 1).
Regarding body mass, an increase in that of the
column, femoral neck and trochanter was observed
after 1 year of HRT. BMD values were 4.7% (P < 0.0004);
2% (P < 0.002); 3% (P < 0.01) higher than the baseline
values, respectively (Table 2).
On comparing pyr and d-pyr baseline values and
those after HRT with BMD values for all analyzed sites,
no correlation could be found with pyr. D-pyr corre-
lated with column BMD in the first month of treat-
Table I - Pyridinium cross-links before and after hormone replacement therapy
After Treatment
 Variable basal 1 month 2 months 4 months 1 year
pyr pmol/umol 41.4 (17) 35.6 (20) 35.2 (21)* 32.3 (15)** 30.7 (17)***
d-pyr pmol/umol 5.0 (3.8) 3.3 (3.9)** 3.4 (4.4) * 4.7 (11.8) 2.9 (5.2)***
***P < 0.0002; **P < 0.001; *P < 0.05 basal vs. after treatment; values in mean and standard deviation.
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5ment (P < 0.02; r = -0.42).
Before starting HRT we found 21 osteoporotic
women (39.6%) (Z score = -2.50 standard deviations
as compared with young adults); 8 osteopenic women
(15%) (Z score between -1.00 and 2.50 standard devia-
tions as compared with young adults). No correlation
between BMD, for either osteoporotic or osteopenic
women with baseline pyr and d-pyr levels, was found
in these patients.
Baseline pyr and d-pyr values did not correlate
with body mass index (BMI), age and time of meno-
pause of the patients.
Baseline BMD was correlated with BMI (column
P < 0.02, r = 0.49; femoral neck P < 0.03, r = 0.46; tro-
chanter P < 0.0001, r = 0.58); age (column P < 0.01, r =
-0.31; femoral neck P < 0.04, r = -0.30; trochanter P <
0.01, r = -0.38); time of menopause (column P < 0.01,
r = -0.36; femoral neck P < 0.03; r = -0.31; trochanter P
< 0.04, r = -0.31).
DISCUSSION
Estrogenic deficiency of menopausal women
leads to an increase in bone resorption, while increase
in formation is secondarily increased due to phenom-
ena occurring in parallel.10 The rate of bone loss is due
to an imbalance between the two processes and it may
be expected that a sensitive resorption marker would
be able to reflect these changes in bone turnover.
According to previous studies, the menopause
leads to a significant increase in urinary pyridinoline
and deoxypyridinoline excretion. Uebelhart et al ob-
served an increase of 128% for pyr and 20% for d-pyr
(in 24-hour urine samples) when compared with pre-
menopausal women in the age range of 31 ± 6 years,11
showing that the resorption process is quite active.
The effect of HRT on the bone mass of meno-
pausal women is mainly due to reduction in resorp-
tion, reflecting a decrease in the frequency of activa-
tion in new bone remodeling units.12,13 In fact, urinary
pyr and d-pyr determinations have shown that these
substances are quite specific markers of bone resorp-
tion. Our findings were that within the first month of
HRT in the case of pyr, and the second month for d-
pyr, a significant decrease could be observed in com-
parison with the pretreatment values. This reinforces
the value of these markers, in addition to demonstrat-
ing their early estrogenic effect on bone.
Uebelhart observed that after 6 months of HRT,
pyr and d-pyr levels returned to premenopausal val-
ues.14 However, our findings showed a continuous de-
crease of 28.9% and 42%, respectively, similar to
Hassager’s findings.1 It is probable that after this length
of HRT, stabilization of the resorption process and
consequently the marker levels occurs, in accordance
with findings by Schlemmer, whose patients were fol-
lowed-up for 10 years.15
Since the postmenopausal bone loss rate is
determined by the ratio of formation to resorption
phenomena, we would expect that sensitive resorp-
tion markers such as pyr and d-pyr would correlate
with mineral bone density as assessed by densitom-
etry. However, except for d-pyr in the first month of
HRT, which correlated with column BMD, no correla-
tion between markers and body mass could be ob-
served, whether at baseline conditions or after treat-
ment. Other authors have obtained the same results,
reinforcing the idea that these markers are not use-
ful for the diagnosis of patients with osteoporosis,
but may help in therapeutic monitoring.14 In contrast
to Schlemmer, who found different pyr and d-pyr val-
ues in osteoporotic and osteopenic patients diag-
nosed by BMD,15 our patients showed no difference
between the groups with or without osteoporosis and
osteopenia. One explanation for this finding is that
it may be due to the fact that bone mass measure-
ment, as assessed by densitometry, is made only at
some sites such as the column, femur or radius and
evaluation of urinary markers reflects collagen deg-
radation of the whole skeleton, including different
segments which may present different turnover and
bone loss rates.16
Most previous studies on urinary pyr and d-pyr
excretion refer to alterations observed in the post-
menopausal period in comparison with the premeno-
pausal condition.5,14,17 There are not many longitudi-
nal studies that extend beyond 6 months of HRT.
CONCLUSION
We conclude that urinary pyridinoline and
deoxypyridinoline excretion decreases during hormone
replacement therapy, reflecting a decrease in the bone
resorption rate. This decrease is early and is therefore
helpful in the evaluation of therapeutic efficacy.
Table 2 - Bone mineral density before and after
hormone replacement therapy
BMD•, g/cm2
Location basal 1 year
Lumbar spine 0.97 (0.18) 1.02 (0.18)***
Neck 0.82 (0.13) 0.84 (0.12)**
Trochanter 0.70 (0.14) 0.72 (0.13)*
***P < 0.0004; **P < 0.002; *P < 0.01 basal vs. after treatment;
values in mean and standard de\viation. • Bone mineral density
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resumo
CONTEXTO: A perda óssea acelerada observada na pós menopausa
é atribuída a um incremento do turnover ósseo, com predomínio da
reabsorção em decorrência da falência ovariana. Ao contrário da
formação tem sido difícil de estabelecer um marcador sensível de
reabsorção.
OBJETIVOS: Avaliar o efeito da terapia de reposicão hormonal (TRH)
na  densidade e nos marcadores  urinários de reabsorção óssea,
piridinolina (PIR) e deoxipiridinolina (D-PIR).
TIPO DE ESTUDO: Estudo coorte de correlação.
LOCAL: Centro universitário de referência.
PACIENTES: 53 mulheres menopausadas há 3,6 ± 5 anos, idade
mediana  de 53 anos.
VARIÁVEIS ESTUDADAS: A excreção urinária de PIR e D-PIR  na
urina de jejum ,analisada por HPLC e expressa em pmol /mmol de
creatinina ,foi avaliada em condições basais e após 1,2,4 e 12
meses de TRH. Realizaram densitometria óssea (DO) em coluna e
fêmur antes e após 12 meses de TRH.
RESULTADOS: A DO após TRH foi 4.7%(P<0.0004); 2%(P<0.002);
and 3%(P<0.01) maior que os valores basais na coluna , colo do
fêmur e trocanter respectivamente. Observou-se um decréscimo dos
valores de PIR e D-PIR precoce e progressivo, atingindo 28,9%
(P<0.0002) e 42% (P<0.0002) após 1ano de TRH respectivamente.
Não houve correlação entre os valores de DO e os de PIR E D-PIR.
CONCLUSÕES: A excreção urinária de PIR e D-PIR constituem um
marcador sensível da reabsorção óssea.O decréscimo precoce a
torna útil na avaliação da eficácia terapeutica.
PALAVRAS-CHAVE: Excreção urinária de piridinolinas. Terapia de
reposição hormomal. Remodelação óssea.
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